Aifang Biology
Custom antibody services for research and diagnostics.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | CNY20.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Aifang Biology, founded in 2018 in Wuhan, China, specializes in the research, development, and production of antibodies and related technical services. The company focuses on providing high-quality, customized antibody services for scientific research and diagnostic applications. Their core offerings encompass a wide range of services including polyclonal and monoclonal antibody development, phosphospecific antibody customization, and immunoassay development kits like ELISA.
The company operates its own research and development center and an SPF (Specific Pathogen Free) animal facility, ensuring control over the entire production process from antigen design to antibody delivery. This integrated approach allows them to serve a diverse client base that includes universities, research institutes, hospitals, and biopharmaceutical companies. Aifang Biology's business model is centered on providing tailored solutions and technical support for complex research projects, positioning itself as a Contract Research Organization (CRO) in the life sciences sector. The company's services are designed to accelerate the research and development pipeline for its clients in fields such as oncology, immunology, and molecular diagnostics.
Keywords: antibody development, CRO, life sciences, monoclonal antibodies, polyclonal antibodies, immunoassay, phosphospecific antibodies, scientific research, diagnostics, biopharmaceutical services